References
- Goldacre B. How to get all trial reported: audit, better data, and individual accountability. Plos Med. 2015;12:e1001821.
- Capuano A, Coats AJS, Scavone C, et al. Disclosure of negative trial results. A call for action. Int J Cardiol. 2015;198:47–48.
- Kesselheim AS, Avorn J. The role of litigation in defining drug risks. Jama. 2007 Jan 17;297(3):308–311.
- Ioannidis JP. How to make more published research true. PLoS Med. 2014 Oct 21;11(10):e1001747.
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Jama. 2000;284:1247–1255.
- Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. Jama. 2001 Nov 21;286(19):2398. author reply 2399-400.
- Lo B, Field MJ. Field. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice. Available from: http://www.ncbi.nlm.nih.gov/books/NBK22940/
- [cited 2016 Aug 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/10/WC500174378.pdf.
- [cited 2016 Aug 2]. Available from: http://www.alltrials.net/find-out-more/why-this-matters/the-alltrials-campaign/.
- European Commission DG Health and Food Safety Public health Medicinal products for human use Clinical trials Regulation. [cited 2016 Aug 2]. Available from: http://ec.europa.eu/health/human-use/clinical-trials/regulation/index_en.htm
- Harriman S, Patel J. When are clinical trials registered? an analysis of prospective versus retrospective registration. Trial. 2016;17:187.
- ICH guideline E2F on development safety update report Step 5. [cited 2016 Aug 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500097061.pdf .
- Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. Jama. 2006 May 17;295(19):2270–2274. Erratum in: JAMA. 2006 Jun 21;295(23):2726.
- Unger JM, Barlow WE, Ramsey SD, et al. The scientific impact of positive and negative phase 3 cancer clinical trials. JAMA Oncol. 2016;2:875–881.
- Condivisione dei dati provenienti dalle sperimentazioni cliniche: l’importanza di un approccio globale. [cited 2016 Aug 2]. Available from: http://www.agenziafarmaco.gov.it/it/content/condivisione-dei-dati-provenienti-dalle-sperimentazioni-cliniche-l%E2%80%99importanza-di-un-approcci).